Resistance to Ara-C up-regulates the activation of NF-κB, telomerase activity and Fas expression in NALM-6 cells

Biological and Pharmaceutical Bulletin

Volumn 30, Issue 11, 2007, Pages 2069-2074

  Kanno, Syu Ichi ^a   Hiura, Takako ^a   Shouji, Ai ^a   Osanai, Yuu ^a   Ujibe, Mayuko ^a   Ishikawa, Masaaki ^a  

^a TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

1 D arabinofuranosylcytosine; Fas; Nuclear factor B; p53; Resistance; Telomerase

Indexed keywords

BAG 1 PROTEIN; CYTARABINE; CYTOTOXIC ANTIBODY; FAS ANTIBODY; FAS ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN BID; PROTEIN P53; TELOMERASE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; UPREGULATION;

ANTIGENS, CD95; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CELL LINE, TUMOR; CYTARABINE; DRUG RESISTANCE, NEOPLASM; FORMAZANS; HUMANS; LEUKEMIA; NF-KAPPA B; TELOMERASE; TETRAZOLIUM SALTS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 36048949092     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.30.2069     Document Type: Article

References (43)

1. Grant S., Adv. Cancer Res., 72, 197-233 (1998).
2. Sen R., Baltimore D., Cell, 47, 921-928 (1986).
3. Shishodia S., Aggarwal B. B., Biochem. Pharmacol., 68, 1071-1080 (2004).
4. Brach M. A., Kharbanda S. M., Herrmann F., Kufe D. W., Mol. Pharmacol., 41, 60-63 (1992).
5. Sreenivasan Y., Sarkar A., Manna S. K., Oncogene, 22, 4356-4369 (2003).
6. Boland M. P., Foster S. J., O'Neill L. A., J. Biol. Chem., 272, 12952-12960 (1997).
7. Das K. C., White C. W., J. Biol. Chem., 272, 14914-14920 (1997).
8. Romano M. F., Lamberti A., Bisogni R., Tassone P., Pagnini D., Storti G., Del Vecchio L., Turco M. C., Venuta S., Gene Ther., 7, 1234-1237 (2000).
9. Jeremias I., Kupatt C., Baumann B., Herr I., Wirth T., Debatin K. M., Blood, 91, 4624-4631 (1998).
10. Wang C. Y., Cusack J. C., Jr., Liu R., Baldwin A. S., Jr., Nat. Med., 5, 412-417 (1999).
11. Berenson J. R., Ma H. M., Vescio R., Semin. Oncol., 28, 626-633 (2001).
12. Akiyama M., Hideshima T., Hayashi T., Tai Y. T., Mitsiades C. S., Mitsiades N., Chauhan D., Richardson P., Munshi N. C., Anderson K. C., Cancer Res., 63, 18-21 (2003).
13. Sinha-Datta U., Horikawa I., Michishita E., Datta A., Sigler-Nicot J. C., Brown M., Kazanji M., Barrett J. C., Nicot C., Blood, 104, 2523-2531 (2004).
14. Greider C. W., Blackburn E. H., Cell, 43, 405-413 (1985).
15. Greider C. W., Blackburn E. H., Nature (London), 337, 331-337 (1989).
16. Devemy E., Li B., Tao M., Horvath E., Chopra H., Fisher L., Nayini J., Creech S., Venugopal P., Yang J., Kaspar C., Hsu W., Preisler H. D., Leuk. Res., 25, 783-791 (2001).
17. Pommier Y., Sordet O., Antony S., Hayward R. L., Kohn K. W., Oncogene, 23, 2934-2949 (2004).
18. Jäättelä M., Oncogene, 23, 2746-2756 (2004).
19. Min Y. H., Lee S., Lee J. W., Chong S. Y., Hahn J. S., Ko Y. W., Br. J. Haematol., 93, 928-930 (1996).
20. Kanno S., Higurashi A., Watanabe Y., Shouji A., Asou K., Ishikawa M., Toxicol. Lett., 152, 149-158 (2004).
21. Kanno S., Hiura T., Ohtake T., Koiwai K., Suzuki H., Ujibe M., Ishikawa M., Clin. Chim. Acta, 377, 144-149 (2007).
22. Kanno S., Matsukawa E., Miura A., Shouji A., Asou K., Ishikawa M., Biol. Pharm. Bull., 26, 964-968 (2003).
23. Capizzi R. L., Yang J. L., Cheng E., Bjornsson T., Sahasrabudhe D., Tan R. S., Cheng Y. C., J. Clin. Oncol., 1, 763-771 (1983).
24. Dumont A., Hehner S. P., Hofmann T. G., Ueffing M., Droge W., Schmitz M. L., Oncogene, 18, 747-757 (1999).
25. Geller H. M., Cheng K. Y., Goldsmith N. K., Romero A. A., Zhang A. L., Morris E. J., Grandison L., J. Neurochem., 78, 265-275 (2001).
26. Franco A. V., Zhang X. D., Van Berkel E., Sanders J. E., Zhang X. Y., Thomas W. D., Nguyen T., Hersey P., J. Immunol., 166, 5337-5345 (2001).
27. Olivier S., Robe P., Bours V., Biochem. Pharmacol., 72, 1054-1068 (2006).
28. Boklan J., Nanjangud G., MacKenzie K. L., May C., Sadelain M., Moore M. A., Cancer Res., 62, 2104-2114 (2002).
29. Haendeler J., Hoffmann J., Rahman S., Zeiher A. M., Dimmeler S., FEBS Lett., 536, 180-186 (2003).
30. Kim J. H., Lee G. E., Kim J. C., Lee J. H., Chung I. K., Mol. Cells, 13, 228-236 (2002).
31. Incles C. M., Schultes C. M., Kelland L. R., Neidle S., Mol. Pharmacol., 64, 1101-1108 (2003).
32. Ward R. J., Autexier C., Mol. Pharmacol., 68, 779-786 (2005).
33. Kuranaga N., Shinomiya N., Mochizuki H., BMC Cancer, 1, 10 (2001).
34. Levine A. J., Cell, 88, 323-331 (1997).
35. Nuessler V., Stotzer O., Gullis E., Pelka-Fleischer R., Pogrebniak A., Gieseler F., Wilmanns W., Leukemia, 13, 1864-1872 (1999).
36. Leonard J. R., D'Sa C., Cahn B. R., Korsmeyer S. J., Roth K. A., Brain Res. Dev. Brain Res., 128, 187-190 (2001).
37. Besirli C. G., Deckwerth T. L., Crowder R. J., Freeman R. S., Johnson E. M., Jr., Cell Death Differ., 10, 1045-1058 (2003).
38. Martin-Aragon S., Mukherjee S. K., Taylor B. J., Ivy S. P., Fu C. H., Ardi V. C., Avramis V. I., Anticancer Res., 20, 139-150 (2000).
39. Muller M., Wilder S., Bannasch D., Israeli D., Lehlbach K., Li-Weber M., Friedman S. L., Galle P. R., Stremmel W., Oren M., Krammer P. H., J. Exp. Med., 188, 2033-2045 (1998).
40. Landowski T. H., Shain K. H., Oshiro M. M., Buyuksal I., Painter J. S., Dalton W. S., Blood, 94, 265-274 (1999).
41. Hofmann T. G., Will H., Cell Death Differ., 10, 1290-1299 (2003).
42. Debatin K. M., Krammer P. H., Oncogene, 23, 2950-2966 (2004).
43. Chan H., Bartos D. P., Owen-Schaub L. B., Mol. Cell Biol., 19, 2098-2108 (1999).